Results 191 to 200 of about 111,871 (303)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. [PDF]

Mol Oncol
Schmitz J, Bartkowiak AL, Rose M, Kolks N, Petzsch P, Solanki V, Stoffel A, Faßbender B, Lepping L, Volkamer J, Köhrer K, Seifert M, Mahmoudi T, Zuiverloon TCM, Niegisch G, Hoffmann MJ.   +15 more
europepmc   +1 more source

Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair

British Journal of Pharmacology, EarlyView.
Background and Purpose Endometriosis is a chronic, hormone‐dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, its impact on lesion regression is limited, possibly due to apoptosis resistance and ...
Yujie Peng, Meng Zhang, Libo Zhu, Wenqiang Qian, Jingjing Yan, Huidi Jiang, Yu Xin, Ying Zhang, Dongli Sun, Weidong Fei, Mengdan Zhao   +10 more
wiley   +1 more source

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer. [PDF]

Nat Commun
Nan Y, Wang K, Hu M, Luo Q, Wu X, Yu X, Zhou X, Chen L, Li B, Cui Z, Liu Z.   +10 more
europepmc   +1 more source

FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐CAT Database Study

Cancer Science, EarlyView.
In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito, Yuko Takano, Osamu Maeda, Hiroki Kawashima, Yuichi Ando   +6 more
wiley   +1 more source

Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance. [PDF]

Pharmaceutics
Xu L, Kong X, Zhang B, Ma H, Li X, Deng Y, Liu W, Ren W, Tang X, Zhang D.   +9 more
europepmc   +1 more source

SOD2‐Superoxide Metabolic Axis Regulates Mitophagy and Modulates TKIs Sensitivity in Head and Neck Squamous Cell Carcinoma

Cancer Science, EarlyView.
Our findings provide compelling evidence that the SOD2‐superoxide metabolic axis functions as a mitochondrial redox checkpoint that governs mitophagy and ultimately shapes TKI sensitivity. ABSTRACT Superoxide dismutase 2 (SOD2) has been implicated in head and neck squamous cell carcinoma (HNSCC), yet its mechanistic contribution in regulating tumor ...
Wan‐Hang Zhou, Shuo‐Jin Huang, An‐Xun Wang   +2 more
wiley   +1 more source

Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications. [PDF]

Cancer Med
Lin DI, Lawrence E, Danziger N, Ye H, Decker B, Gjoerup O, Graf RP, Ross JS, Huang RSP, Elvin JA, Mata DA, McKay RR.   +11 more
europepmc   +1 more source

A novel glucose beta‐hydroxybutyrate combination improves hypoglycaemia recovery and patient‐reported outcomes in type 1 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Hypoglycaemia remains a major barrier to optimal diabetes management. Current treatments based on simple sugars have limitations, including rapid glucose fluctuations and persistent neuroglycopenic symptoms. We investigated FLO23011, a novel multi‐substrate energy formulation containing glucose and beta‐hydroxybutyrate, as a superior ...
D. Russell‐Jones, V. Smout, S. Roy, G. Myers, R. Littlewood, F. Shojaee‐Moradie   +5 more
wiley   +1 more source

Intersecting Anemias: PARP Inhibitor-Induced Toxicity and Autoimmune Hemolysis-A Case Report. [PDF]

EJHaem
Dereme J, Asonitis K, Grandoni F, Liapi A, Sarivalasis A, Tsilimidos G.   +5 more
europepmc   +1 more source

Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. [PDF]

Cancer Biol Ther
Tomas EJ, Davis J, Ramos Valdes Y, Shepherd TG.   +3 more
europepmc   +1 more source